EP0563175A1 - Procede de construction de sequences leaders synthetiques - Google Patents

Procede de construction de sequences leaders synthetiques

Info

Publication number
EP0563175A1
EP0563175A1 EP92901668A EP92901668A EP0563175A1 EP 0563175 A1 EP0563175 A1 EP 0563175A1 EP 92901668 A EP92901668 A EP 92901668A EP 92901668 A EP92901668 A EP 92901668A EP 0563175 A1 EP0563175 A1 EP 0563175A1
Authority
EP
European Patent Office
Prior art keywords
sequence encoding
dna sequence
yeast
signal peptide
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP92901668A
Other languages
German (de)
English (en)
Inventor
Lars Christiansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of EP0563175A1 publication Critical patent/EP0563175A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Abstract

Vecteur clonant d'expression de la levure comportant la séquence suivante: 5'-SP-Xn-3'-RS-5'-Xm-(nZT)p-Xq-PS-*gène*-3', dans laquelle SP représente une séquence d'ADN codant un peptide signal; Xn représente une séquence d'ADN codant n acides aminés, où n est 0 ou un nombre entier compris entre 1 et environ 10; RS représente un site de reconnaissance d'endonucléase de restriction situé au niveau de la jonction entre Xn et Xm; Xm représente une séquence d'ADN codant m acides aminés, où m est 0 ou un nombre entier compris entre 1 et environ 10; (NZT)p représente une séquence d'ADN codant Asn-Xaa-Thr, où p est 0 ou 1; Xq représente une séquence d'ADN codant q acides aminés, où q est 0 ou un nombre entier compris entre 1 et environ 10; PS représente une séquence d'ADN codant un peptide qui définit un site de maturation de levure; et *gène* représente une séquence d'ADN codant un polypeptide hétérologue. Le vecteur peut servir à la construction de séquences peptidiques leaders synthétiques par l'introduction de fragments aléatoires d'ADN dans le site "RS", par la culture d'une cellule de levure transformée par ce vecteur, et par le dépistage dans cette culture d'une sécretion du polypeptide hétérologue.
EP92901668A 1990-12-19 1991-12-18 Procede de construction de sequences leaders synthetiques Ceased EP0563175A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK300090A DK300090D0 (da) 1990-12-19 1990-12-19 Fremgangsmaade til fremstilling af leadersekvenser
DK3000/90 1990-12-19

Publications (1)

Publication Number Publication Date
EP0563175A1 true EP0563175A1 (fr) 1993-10-06

Family

ID=8118017

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92901668A Ceased EP0563175A1 (fr) 1990-12-19 1991-12-18 Procede de construction de sequences leaders synthetiques

Country Status (17)

Country Link
EP (1) EP0563175A1 (fr)
JP (1) JPH06503957A (fr)
KR (1) KR930703450A (fr)
AU (1) AU660161B2 (fr)
CA (1) CA2098731A1 (fr)
CZ (1) CZ119293A3 (fr)
DK (1) DK300090D0 (fr)
FI (1) FI932831A (fr)
HU (1) HUT68751A (fr)
IE (1) IE914433A1 (fr)
IL (1) IL100408A0 (fr)
MX (1) MX9102684A (fr)
NZ (1) NZ241011A (fr)
PT (1) PT99848A (fr)
SK (1) SK62593A3 (fr)
WO (1) WO1992011378A1 (fr)
ZA (1) ZA919932B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI92601C (fi) * 1992-03-11 1994-12-12 Marja Makarow Menetelmä hyötyproteiinien erittämiseksi hiivoista
US5538863A (en) * 1993-07-01 1996-07-23 Immunex Corporation Expression system comprising mutant yeast strain and expression vector encoding synthetic signal peptide
US5639642A (en) * 1994-06-16 1997-06-17 Novo Nordisk A/S Synthetic leader peptide sequences
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
ZA954983B (en) * 1994-06-17 1996-02-14 Novo Nordisk As N-terminally extended proteins expressed in yeast
HRP940432B1 (en) * 1994-08-05 2003-10-31 Pliva Pharm & Chem Works Dna sequences encoding biosynthetic insulin precursors and process for preparation of insulin
CN1182451A (zh) 1995-03-17 1998-05-20 诺沃挪第克公司 新的内切葡聚糖酶
PT1975177E (pt) 1996-03-01 2011-07-26 Novo Nordisk As Peptídeo supressor do apetite, sua composição e uso
US6083910A (en) 1996-12-13 2000-07-04 Chiron Corporation Therapeutic uses of resolved intact or clipped native-sequence PDGF-BB dimers
EP1049790A1 (fr) 1998-01-23 2000-11-08 Novo Nordisk A/S Procede servant a preparer des polypeptides souhaites dans de la levure
KR20030004315A (ko) 1999-12-29 2003-01-14 노보 노르디스크 에이/에스 효모에서 개선된 발효 수율을 갖는 인슐린 선구물질 및인슐린 선구물질 유사체의 제조 방법
AT410217B (de) * 2000-06-15 2003-03-25 Cistem Biotechnologies Gmbh Vektor und ein verfahren zur expression und selektion randomisierter peptid-sequenzen
EP1373493B1 (fr) 2001-03-22 2013-07-31 Novo Nordisk Health Care AG Derive du facteur vii de coagulation
ATE532858T1 (de) 2001-09-27 2011-11-15 Novo Nordisk Healthcare Ag Menschliche gerinnungsfaktor-vii-polypeptide
CN101870729A (zh) 2003-09-09 2010-10-27 诺和诺德医疗保健公司 凝固因子ⅶ多肽
EP1687428A1 (fr) 2003-11-14 2006-08-09 Novo Nordisk A/S Procede de fabrication d'insuline acylee
ATE517119T1 (de) 2003-12-03 2011-08-15 Novo Nordisk As Einzelketteninsulin
WO2005078116A1 (fr) * 2004-01-16 2005-08-25 Qiuyun Liu Methode permettant d'isoler de peptides antibacteriens et peptides isoles
RU2412199C2 (ru) 2005-04-18 2011-02-20 Ново Нордиск А/С Варианты ил-21
US9056921B2 (en) 2005-08-16 2015-06-16 Novo Nordisk A/S Method for making mature insulin polypeptides
EP1926817A2 (fr) 2005-09-14 2008-06-04 Novo Nordisk Health Care AG Polypeptides du facteur vii de coagulation humain
JP5202338B2 (ja) 2006-02-27 2013-06-05 ノボ・ノルデイスク・エー／エス 新規インシュリン誘導体
WO2008037735A1 (fr) 2006-09-27 2008-04-03 Novo Nordisk A/S Procédé de fabrication de polypeptides d'insuline mature
ES2558930T3 (es) 2007-08-13 2016-02-09 Novo Nordisk A/S Análogos de la insulina de acción rápida
EP2178910B1 (fr) 2007-08-15 2014-10-08 Novo Nordisk A/S Insulines avec une fraction acyle comprenant des unités répétitives d'alkylène glycol contenant des acides aminés
CA2695970A1 (fr) 2007-08-15 2009-02-19 Novo Nordisk A\S Analogues de l'insuline comprenant un fragment acyle et alkylene glycol
WO2010103038A1 (fr) 2009-03-11 2010-09-16 Novo Nordisk A/S Variants de l'interleukine 21 se liant de manière antagoniste au récepteur de l'il-21
EP2454281B1 (fr) 2009-07-17 2018-11-14 Omeros Corporation Isoformes de masp comme inhibiteurs des complements d'activation
EP2504355B1 (fr) 2009-11-25 2015-07-22 Novo Nordisk A/S Procédé de fabrication de polypeptides
ES2583259T3 (es) 2009-12-01 2016-09-20 Novo Nordisk A/S Nuevas liasas alfa-amidantes de peptidil alfa-hidroxiglicina
CN102791730A (zh) 2010-01-22 2012-11-21 诺沃—诺迪斯克有限公司 低度o-糖基化的fgf21的制备方法
US9815876B2 (en) 2010-03-05 2017-11-14 Omeros Corporation Chimeric inhibitor molecules of complement activation
CA2806399A1 (fr) * 2010-07-28 2012-02-02 Smartcells, Inc. Polypeptides d'insuline exprimes de facon recombinante et utilisations de ceux-ci
ES2676029T3 (es) 2012-02-09 2018-07-16 Var2 Pharmaceuticals Aps Direccionamiento de glicanos de sulfato de condroitina
WO2014060401A1 (fr) 2012-10-15 2014-04-24 Novo Nordisk Health Care Ag Polypeptides de facteur vii de coagulation
EP3004156A1 (fr) 2013-06-07 2016-04-13 Novo Nordisk A/S Procédé de fabrication de polypeptides d'insuline mature
JP6275847B2 (ja) * 2014-02-28 2018-02-07 ノヴォ ノルディスク アー／エス アルファ接合因子プロペプチドバリアント
EP3821244A1 (fr) 2018-07-13 2021-05-19 Varct Diagnostics ApS Isolement de cellules circulantes d'origine foetale à l'aide d'une protéine de malaria recombinante var2csa

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK463887D0 (da) * 1987-09-07 1987-09-07 Novo Industri As Gaerleader
CA1340772C (fr) * 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression et secretion de proteines heterologues dans une levure au moyen de sequences leader tronquees du facteur alpha
WO1990001063A1 (fr) * 1988-07-23 1990-02-08 Delta Biotechnology Limited Nouvelles sequences conductrices secretoires
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9211378A1 *

Also Published As

Publication number Publication date
JPH06503957A (ja) 1994-05-12
PT99848A (pt) 1993-06-30
NZ241011A (en) 1993-04-28
HU9301801D0 (en) 1993-10-28
MX9102684A (es) 1992-06-01
SK62593A3 (en) 1993-10-06
FI932831A0 (fi) 1993-06-18
ZA919932B (en) 1992-08-26
DK300090D0 (da) 1990-12-19
IL100408A0 (en) 1992-09-06
CA2098731A1 (fr) 1992-06-19
IE914433A1 (en) 1992-07-01
KR930703450A (ko) 1993-11-30
CZ119293A3 (en) 1994-02-16
WO1992011378A1 (fr) 1992-07-09
AU9134891A (en) 1992-07-22
FI932831A (fi) 1993-06-18
AU660161B2 (en) 1995-06-15
HUT68751A (en) 1995-07-28

Similar Documents

Publication Publication Date Title
AU660161B2 (en) A method of constructing synthetic leader sequences
AU693569B2 (en) Synthetic leader peptide sequences
EP0792367B1 (fr) Structure d'adn codant le peptide signal de yap3
JP3730255B2 (ja) イーストにおいて発現されたｎ末端に伸長した蛋白質
EP0378567B1 (fr) Peptides guides synthetiques secretes dans des levures
US6500645B1 (en) N-terminally extended proteins expressed in yeast
EP0387319B1 (fr) Sequences conductrices secretoires
EP0868523B1 (fr) Vecteur pour l'expression de proteines a prolongement n-terminal dans les cellules de levure
RU2167939C2 (ru) Способ продуцирования полипептида в дрожжах
CA2192942C (fr) Sequences de peptides leaders synthetiques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19930614

17Q First examination report despatched

Effective date: 19931208

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19960524